Unique New Product Demonstrates Efficacy and Performance

reading time
Article | 24.10.2020

Monimax® is a new product that combines the strengths of the synthetic compound nicarbazin with the ionophore monensin, resulting in a unique new product for coccidiosis control. 

  • Monensin interacts with the parasite during the motile stage (sporozoites and merozoites) and does not penetrate the intestinal cells. 
  • Nicarbazin interacts later during the lifecycle of the parasite and can penetrate the intestinal cells (first and second generation schizonts).

The different mode of action of monensin and nicarbazin results in an optimal efficacy. There is a synergistic effect between nicarbazin and monensin, resulting in a high performing product (Figure 1). 

Figure 1. The synergistic effect between nicarbazin and monensin

Synergy of two strong active compounds

An anticoccidial sensitivity trial (AST) has demonstrated this synergistic effect between nicarbazin and monensin: the combination of both products performed better than the products individually. Monensin at 40 ppm did not reduce lesions for any of the Eimeria species. Nicarbazin at 40 ppm significantly reduced the lesions for E. tenella but the other Eimeria species were not significantly affected. The combination of nicarbazin and monensin (both at 40 ppm) significantly reduced the lesions for all Eimeria species. These results are proof of the synergistic effect between monensin and nicarbazin (Table 1). 

Table 1. Lesion scoring results of different treatment groups

Although Monimax® is a new product, the active compounds have been on the market for many years, so development of resistance is a legitimate concern. Recent feedback from the field indeed suggests reduced efficacy of the often used nicarbazin/narasin combination product currently on the market. For this reason, a meta-analysis was performed to evaluate the effectiveness of Monimax® against recent Eimeria field strains in comparison to nicarbazin/narasin. 

The meta-analysis was performed using the data from 27 different ASTs conducted over a seven year period (2013-2019). The Eimeria isolates were collected from 13 different countries with different anticoccidial control programs. The sensitivity trials were conducted in two different research institutes, using a comparable, standardized AST protocol (Figure 2). 

Figure 2. The standardized protocol for an anticoccidial sensitivity test (AST)

In short, groups of cage-reared birds were supplemented with Monimax® or nicarbazin/narasin starting two days before oral inoculation with different Eimeria field strains. About six days after inoculation, the severity of lesion scores (according to Johnson and Reid, 1970) and performance was determined and compared to an uninfected, untreated control group (UUC) and an infected, untreated control group (IUC). All coccidiostats were used at the currently registered European dosages. 

Average daily gain (ADG), average daily feed intake (ADI) and feed conversion ratio (FCR) over a one-week period were compared in a meta-analysis from 27 standardized sensitivity trials. In-feed application of Monimax® was compared to both control groups and to the inclusion of the nicarbazin/narasin combination. Monimax® resulted in significantly higher values for all measured parameters (ADG, ADI and FCR) compared to the IUC (Table 2). 

Table 2. The different performance parameters in comparison with both control groups
Table 3. Lesion scoring results per species according to the Johnson and Reid scoring system

Although the difference is not statistically significant, Monimax® resulted in better performance compared to the nicarbazin/narasin combination. Lesion scores were determined according to the Johnson and Reid scoring system and the least square mean (LSM) per species is shown in Table 3. 

The combination of nicarbazin and narasin did not deliver a significant reduction of E. acervulina, whereas Monimax® resulted in a significant reduction for all species (E. acervulinaE. maxima, and E. tenella) compared to the IUC. Monimax® resulted in significantly lower lesions both for E. acervulina and E. maxima compared to nicarbazin/narasin. 

Control of Eimeria acervulina is very important as prevalence data (collected from Aviapp®) demonstrate that Eimeria acervulina is the most frequently diagnosed Eimeria when monitoring broilers in Europe, followed by Eimeria maxima and Eimeria tenella (Figure 3). When plotting out lesion scoring data by the age of the birds from more than 4,000 flocks over the last three years, Eimeria acervulina is the main driver of the total mean lesion score. 

Figure 3. Total mean lesion score (yellow) and average lesion scores of Eimeria acervulina (green), Eimeria maxima (blue) and Eimeria tenella (red) by age of bird. The graph comprises data from 4,692 European flocks scored between 2016 - 2019


Monimax® is a new anticoccidial on the European market. The combination of nicarbazin and monensin results in a product with proven efficacy because of the synergistic effect of the two compounds. Monimax® has proven to significantly increase zootechnical and parasitological parameters in an extensive study including data of 27 standardized sensitivity trials. Results were improved in comparison to birds receiving the nicarbazin/narasin combination due to the significantly better control of Eimeria acervulina and Eimeria maxima. From a practical point of view, this is especially important as E. acervulina is the most prevalent Eimeria species in Europe.


This article article originally appeared in International Poultry Production, Vol 28 No 7.
global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us


Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .




North America


South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.


United States

Click here to visit the local website or close this popup to stay on the global website.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now